TF and prostate cancer: Consistently, we found lower serum ferritin (SMD: −1.25; 95% CI: −2.34, −0.16; P = 0.024) and transferrin saturation (SMD: −1.19; 95% CI: –2.34, −0.05; P = 0.042) levels in patients with prostate cancer compared with that in controls.